A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn#s Disease Recurrence

Grants and Contracts Details

StatusFinished
Effective start/end date11/12/20 → 11/3/23

Funding

  • Pharmaceutical Research Associates: $43,358.00